0001126234-20-000062.txt : 20200407
0001126234-20-000062.hdr.sgml : 20200407
20200407175820
ACCESSION NUMBER: 0001126234-20-000062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200403
FILED AS OF DATE: 20200407
DATE AS OF CHANGE: 20200407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCracken Joseph S
CENTRAL INDEX KEY: 0001632454
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35342
FILM NUMBER: 20780628
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LUMOS PHARMA, INC.
CENTRAL INDEX KEY: 0001126234
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 421491350
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4200 MARATHON BLVD.
STREET 2: SUITE 200
CITY: AUSTIN
STATE: TX
ZIP: 78756
BUSINESS PHONE: 512-215-2630
MAIL ADDRESS:
STREET 1: 4200 MARATHON BLVD.
STREET 2: SUITE 200
CITY: AUSTIN
STATE: TX
ZIP: 78756
FORMER COMPANY:
FORMER CONFORMED NAME: NEWLINK GENETICS CORP
DATE OF NAME CHANGE: 20001012
4
1
wf-form4_158629668273144.xml
FORM 4
X0306
4
2020-04-03
0
0001126234
LUMOS PHARMA, INC.
(LUMO)
0001632454
McCracken Joseph S
4200 MARATHON BLVD
SUITE 200
AUSTIN
TX
78756
1
0
0
0
Common Stock
2020-04-03
4
A
0
709
0
A
709
D
Stock Option (Right to Buy)
7.78
2020-04-03
4
A
0
5684
0
A
2030-04-02
Common Stock
5684.0
5684
D
Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2010 Non-Employee Director Stock Award Plan (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of three successive annual installments beginning on April 3, 2021, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
Grant to the Reporting Person of a nonstatutory stock option under the Plan. One-third of the shares vest on the one-year anniversary of the grant date and the remaining two-thirds of the shares vest in a series of 24 successive equal monthly installments thereafter, subject to the Reporting Persons's continuous service as of such dates. The option expires ten years after the date of grant, unless it expires sooner pursuant to the terms of the Plan.
/s/ Ryan Trytten, attorney-in-fact
2020-04-07